SCHEMBL21743152

SCHEMBL21743152

CC(=O)c1cc(C)nc(C2CC2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
POLB P06746 1/20 0.37
LDHA P00338 1/20 0.37
KDM5A P29375 5/20 0.37
CA5A P35218 1/20 0.36
TLR9 Q9NR96 1/20 0.35
TLR8 Q9NR97 1/20 0.35
TLR7 Q9NYK1 1/20 0.35
PROKR1 Q8TCW9 1/20 0.35
KDM4E B2RXH2 2/20 0.35
USP2 O75604 1/20 0.35
HPGD P15428 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ACKR3 P25106 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
KMT2A Q03164 1/20 0.34
GAA P10253 1/20 0.34
IDO1 P14902 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21326171 0.86 POLB (0.44) NPC1RAB9APOLBKDM5APROKR1
SCHEMBL18176056 0.84 POLB (0.39) POLBKDM5APROKR1KDM4EUSP2
SCHEMBL26918366 0.81 POLB (0.36) POLBCA5APROKR1KDM4ESMN1; SMN2
SCHEMBL1424936 0.79 KMO (0.44) NPC1RAB9APOLBKDM5APROKR1
SCHEMBL26918999 0.79 ALOX15 (0.46) POLBKDM5ACA5AKDM4ESMN1; SMN2
SCHEMBL24213989 0.78 KMO (0.46) POLBKDM5ATLR8PROKR1KDM4E
Hydrochloric Acid SCHEMBL1425501 0.78 KMO (0.43) NPC1RAB9APOLBKDM5APROKR1
SCHEMBL5762468 0.78 NPC1 (0.50) NPC1RAB9ACA5AKDM4EHPGD
SCHEMBL21742932 0.77 KDM5A (0.41) POLBKDM5ATLR9TLR8TLR7
SCHEMBL29998471 0.76 POLB (0.38) POLBKDM5AKDM4EHPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11319321-B2 [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2022-05-03 US disclosed
US-20200055858-A1 [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2020-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200055858-A1 [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS PDE2A, PDE12, PDE5A NPC1 3189/4885RAB9A 1910/4885POLB 740/4885
US-11319321-B2 [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors PDE2A, PDE12, PDE5A NPC1 3189/4885RAB9A 1910/4885POLB 740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.